利好！这家公司，深夜大涨

Core Viewpoint - The article highlights the significant rise in the stock price of Dynavax Technologies, driven by Sanofi's announcement to acquire the company for approximately $2.2 billion, aiming to enhance its vaccine product line [1][6]. Group 1: Stock Market Performance - On December 24, U.S. stock indices opened slightly lower, with the Dow Jones Industrial Average up by 0.14%, the Nasdaq down by 0.09%, and the S&P 500 up by 0.03% [2][3]. - Dynavax Technologies experienced a substantial stock price increase, with a rise of over 38% at the time of reporting [4][5]. Group 2: Acquisition Details - Sanofi announced its agreement to acquire all outstanding shares of Dynavax Technologies at a cash price of $15.5 per share [6]. - The acquisition, valued at approximately $2.2 billion, aims to expand Sanofi's vaccine product line, which currently focuses on influenza vaccines [6]. - Through this acquisition, Sanofi will gain access to an already marketed hepatitis B vaccine and an experimental shingles vaccine in early human trials, strengthening its position in the adult vaccination market [6].